(NasdaqGM:EYPT), – Phase 3 LUGANO and LUCIA clinical trials for DURAVYU(TM) in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program consisting of two identical non-inferiority trials, COMO and CAPRI; first patient dosing anticipated in Q1 2026 – – Announced preclinical […]

(NasdaqGM:GUTS), BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November

(NASDAQ:AVIR), BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12, 2025, at 4:30 p.m.

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) — Partner1 is proud to announce its recognition on the Inc. Power Partner Awards. The prestigious list honors B2B organizations that have proven track records supporting entrepreneurs and helping startups grow. Companies on the Inc. Power Partner list received top marks from clients for being instrumental in helping

(NASDAQ:PASG), PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

(NasdaqGM:MLTX), Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027 Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC.

Bullish Selects GenieAI as Portfolio and Risk Analytics Provider for Professional Trader Competition GlobeNewswire November 05, 2025 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — GenieAI, a leading AI-powered portfolio and risk management platform for digital asset managers, has been selected by Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies GlobeNewswire November 05, 2025 atai Life Sciences' shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on

HTVRONT A300 Auto Hat Heat Press Brings True Automation to Hat Making Empowering creators and small businesses with one-tap automation and powerful pressure GlobeNewswire November 05, 2025 SACRAMENTO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — HTVRONT, a leading innovator in heat press and crafting technology, today announced the launch of its all-new HTVRONT A300 Auto